Literature DB >> 20976633

Incidental carcinomas detected by PET/CT scans in patients with malignant lymphoma.

Kazuya Sato1, Katsutoshi Ozaki, Shin-ichiro Fujiwara, Iekuni Oh, Tomohiro Matsuyama, Ken Ohmine, Takahiro Suzuki, Masaki Mori, Tadashi Nagai, Kazuo Muroi, Keiya Ozawa.   

Abstract

According to the international working group response criteria for malignant lymphoma revised in 2007, 18F-fluorodeoxyglucose positron emission tomography (¹⁸FDG-PET) combined with or without computed tomography (CT) is recommended for pre-treatment staging and response assessment among patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. Recently, along with the widespread use of PET/CT, unexpected uptake and accumulation of ¹⁸FDG has been reported. Discussed in the present report are patients with malignant lymphoma and second primary carcinomas that were incidentally found by PET/CT. A total of 497 consecutive PET/CT were performed on 290 patients with malignant lymphoma in our institution from April 2008 through March 2010. Eight patients (2.8%) had pathologically confirmed second primary carcinomas consisting of 4 colon cancers, 3 lung cancers, and 1 pancreatic cancer. Two cases were diagnosed at the initial staging, and the others were detected after treatment for lymphoma. It is noteworthy that PET revealed high accumulations of ¹⁸FDG in 5 (62.5%) of the 8 patients without corresponding tumors in conventional CT. All of the 4 patients with colon carcinoma underwent curative surgery. The present study suggests that incidental findings by PET in malignant lymphoma can lead to early detection and successful treatment of second malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20976633     DOI: 10.1007/s12185-010-0702-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  9 in total

Review 1.  18F-FDG imaging: pitfalls and artifacts.

Authors:  Mohei M Abouzied; Elpida S Crawford; Hani Abdel Nabi
Journal:  J Nucl Med Technol       Date:  2005-09

2.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

3.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.

Authors:  H Abdel-Nabi; R J Doerr; D M Lamonica; V R Cronin; P J Galantowicz; G M Carbone; M B Spaulding
Journal:  Radiology       Date:  1998-03       Impact factor: 11.105

4.  How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?

Authors:  Guohui Wang; Eddie W F Lau; Ramdave Shakher; Danny Rischin; Robert E Ware; Emily Hong; David S Binns; Annette Hogg; Elizabeth Drummond; Rodney J Hicks
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

5.  Detection of unexpected additional primary malignancies with PET/CT.

Authors:  Takayoshi Ishimori; Pavni V Patel; Richard L Wahl
Journal:  J Nucl Med       Date:  2005-05       Impact factor: 10.057

6.  Incidental PET/CT findings in the cancer patient: how should they be managed?

Authors:  John S Beatty; Hadyn T Williams; Beau A Aldridge; Matthew P Hughes; Viren S Vasudeva; Angela L Gucwa; George S David; D Scott Lind; E James Kruse; James M McLoughlin
Journal:  Surgery       Date:  2009-08       Impact factor: 3.982

Review 7.  The role of FDG-PET scans in patients with lymphoma.

Authors:  Pamela Seam; Malik E Juweid; Bruce D Cheson
Journal:  Blood       Date:  2007-08-20       Impact factor: 22.113

8.  Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison.

Authors:  Harry Agress; Benjamin Z Cooper
Journal:  Radiology       Date:  2003-12-29       Impact factor: 11.105

9.  Application of positron emission tomography imaging to cancer screening.

Authors:  S Yasuda; M Ide; H Fujii; T Nakahara; Y Mochizuki; W Takahashi; A Shohtsu
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

  9 in total
  5 in total

1.  Metachronous pancreatic acinar cell carcinoma discovered in early stage during follow-up of breast cancer: report of a case.

Authors:  Satoshi Hayama; Makoto Ohmi; Atsuya Yonemori; Takumi Yamabuki; Hitoshi Inomata; Kazuyoshi Nihei; Satoshi Hirano
Journal:  Clin J Gastroenterol       Date:  2012-07-21

2.  Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer.

Authors:  Y Sone; A Sobajima; T Kawachi; S Kohara; K Kato; S Naganawa
Journal:  Br J Radiol       Date:  2014-08-13       Impact factor: 3.039

3.  Follicular Lymphoma mimicking Metastatic Nodes on the F-18 FDG PET/CT and MRI for Staging of Endometrial Cancer.

Authors:  Seok-Nam Yoon
Journal:  Nucl Med Mol Imaging       Date:  2016-11-05

4.  PET/CT incidental detection of second tumor in patients investigated for pancreatic neoplasms.

Authors:  Lucia Moletta; Sergio Bissoli; Alberto Fantin; Nicola Passuello; Michele Valmasoni; Cosimo Sperti
Journal:  BMC Cancer       Date:  2018-05-04       Impact factor: 4.430

Review 5.  The clinical application of 18F-FDG PET/CT in pancreatic cancer: a narrative review.

Authors:  Yongzhu Pu; Chun Wang; Sheng Zhao; Ran Xie; Lei Zhao; Kun Li; Conghui Yang; Rui Zhang; Yadong Tian; Lixian Tan; Jindan Li; Shujuan Li; Long Chen; Hua Sun
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.